These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 17319472)

  • 1. Effects of eprosartan on target organ protection.
    de la Sierra A
    Vasc Health Risk Manag; 2006; 2(1):79-85. PubMed ID: 17319472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
    Schrader J; Lüders S; Kulschewski A; Hammersen F; Plate K; Berger J; Zidek W; Dominiak P; Diener HC;
    Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
    Larsen K; Hornnes N; Boysen G
    Stroke; 2006 Jun; 37(6):1357; author reply 1358. PubMed ID: 16645128
    [No Abstract]   [Full Text] [Related]  

  • 4. Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
    Johnston SC
    Nat Clin Pract Neurol; 2006 Jan; 2(1):24-5. PubMed ID: 16932517
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Rupp H
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S25-9. PubMed ID: 18093411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Dowlatshahi D; Hill MD
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
    Bloch MJ; Basile J
    J Clin Hypertens (Greenwich); 2005 Aug; 7(8):489-92. PubMed ID: 16103761
    [No Abstract]   [Full Text] [Related]  

  • 9. Eprosartan: a review of its use in the management of hypertension.
    Robins GW; Scott LJ
    Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eprosartan: a review of its use in hypertension.
    Plosker GL
    Drugs; 2009; 69(17):2477-99. PubMed ID: 19911859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not all antihypertensive agents protect equally well].
    MMW Fortschr Med; 2006 Aug; 148(33-34):52. PubMed ID: 16981390
    [No Abstract]   [Full Text] [Related]  

  • 13. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
    Leu HB; Charng MJ; Ding PY
    Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Shlyakhto E
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV; Rudmann MA
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
    Voors AA; van de Wal RM; Hartog JW; Vijn RG; Hummel YM; Plokker TW; van Veldhuisen DJ; Jaarsma W
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):33-40. PubMed ID: 20229056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
    Blankestijn PJ; Rupp H
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical profile of eprosartan.
    Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
    Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.
    Labiós M; Martínez M; Gabriel F; Guiral V; Ruiz-Aja S; Beltrán B; Muñoz A
    J Hum Hypertens; 2008 Jul; 22(7):493-500. PubMed ID: 18385744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.